In a recent update, ABVC BioPharma, Inc. has announced its new direction in the fields of oncology and hematology, aiming to tap into the lucrative cancer market. The company, known for its development of therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, revealed its plans for combination therapy for cancer treatment and immunity booster dietary supplements. This multi-pronged approach is based on the use of Maitake Mushroom as a source for both pharmaceutical compounds and dietary supplements.
ABVC BioPharma is currently involved in marketing dietary supplements, as well as conducting clinical trials for pharmaceutical compounds derived from the Maitake Mushroom. The company has already begun selling dietary supplements in the US, Canada, and Asia, while also pursuing clinical trials at esteemed medical institutions in these regions. Furthermore, the company expects its wholly-owned subsidiary, CDMO BioKey, Inc. based in Fremont, to play a significant role in revenue generation.
The impact of these developments on ABVC BioPharma is expected to be substantial. By entering the cancer market, which is valued in the several hundred billion dollars range, the company aims to not only create a strong foothold but also contribute to the advancement of oncology and hematology. Considering ABVC BioPharma’s successful track record in other therapeutic areas, its foray into the cancer field holds great promise.
The use of Maitake Mushroom as the common source for both pharmaceutical compounds and dietary supplements is a notable strategic move. This ensures efficient utilization of resources while also catering to a broader consumer base. The company’s dual focus on developing novel therapies through clinical trials and marketing dietary supplements indicates a commitment to versatility and addressing the diverse needs of patients and consumers.
ABVC BioPharma’s decision to initiate clinical trials at prestigious medical institutes in the US and Asia showcases its dedication to rigorous scientific research and validation. Collaborating with renowned institutions ensures the credibility and acceptance of the company’s therapies within the medical community. This will likely enhance ABVC BioPharma’s reputation and increase its chances of success in the competitive oncology and hematology market.
Comments